Abstract
Transposable Elements (TE) are mobile DNA elements that can replicate and insert themselves into different locations within the host genome. Their propensity to self-propagate has a myriad of consequences and yet their biological significance is not well-understood. Indeed, retrotransposons have evaded evolutionary attempts at repression and may contribute to somatic mosaicism. Retrotransposons are emerging as potent regulatory elements within the human genome. In the diseased state, there is mounting evidence that endogenous retroelements play a role in etiopathogenesis of inflammatory diseases, with a disposition for both autoimmune and neurological disorders. We postulate that active mobile genetic elements contribute more to human disease pathogenesis than previously thought.
Introduction
Discovered in the context of maize kernel mosaicism (), transposons are present in virtually all eukaryotes and mobilize from one chromosomal loci to another through either a DNA or RNA intermediate. They parallel viruses in many ways—with regards to their structure and function as they ensure their own survival by way of reintegration (). Human Endogenous Retroviruses (HERV) and Long-Interspersed Nuclear Element-1 (LINE-1) are two main classes of retrotransposons and are mobilized through a “copy and paste” mechanism. HERV and LINE-1 insertions have accumulated throughout evolution and host genomes have simultaneously coevolved with these mobile elements by employing a variety of factors to suppress aberrant activity (). LINE-1 somatic retrotransposition has been well-demonstrated to occur in neuronal lineage, however the significance of retroelement activity to normal brain function remains uncertain. Furthermore, the contribution of these elements to the symptomatology of neurodegenerative diseases is a topic of recent exploration. We begin this review with a brief overview of the types of transposable elements and their methods of integration. We will then discuss the consequences of retrotransposon activity and their dynamic relationship with various regulators. Finally, we will review the direct influence of these elements on CNS function and their contribution to disease and neuroinflammation.
Transposable Elements: An Overview
Transposable elements comprise at least 45% of the human genome while coding sequences occupy <3% (). These highly repetitive strands of “junk” DNA are capable of generating new copies in the human germline and certain somatic tissues. Transposable elements (TE) can be classified as either DNA transposons or retro (RNA) transposons. The mobilization of these elements is referred to as either transposition or retrotransposition. DNA transposons, known as Class I transposons, are flanked by terminal inverted repeats and transpose with a “cut and paste” mechanism whereby the sequence is excised from one region, catalyzed by a transposase enzyme, and integrated into a separate region in the genome [Figure 1; (, )]. DNA transposons constitute 3% of the genome and are no longer active in most mammals (, ).
Figure 1
Retrotransposons, also referred to as Class I transposable elements, integrate into the genome via an RNA intermediate, utilizing a “copy and paste” mechanism; this allows the active retroelements to retain their original location in the genome while accumulating copy numbers elsewhere. These retroelements can be further classified based on the presence of long terminal repeats (LTR) in the sequence. Elements such as Mammalian apparent LTR-retrotransposons (MaLR) and human endogenous retroviruses (HERV) both contain LTR sequences that flank internal coding regions (
Non-LTR retrotransposons can be further classified into two subtypes: LINE (Long Interspersed Nuclear Elements) and SINE (Short Interspersed Nuclear Elements) (Figure 1). Together, LINE and SINE comprise ~33% of the human genome (
HERV
HERV copies comprise 5–8% of the human genome, with some lower estimates at 1% (
Transcriptionally active HERV subfamilies have more recently been implicated as pathophysiological contributors to various disorders (Table 1). An initial 1993 study reported that the addition of herpes simplex virus type 1 (HSV-1) to primary leptomeningeal cells isolated from a patient with multiple sclerosis (MS) lead to robust co-expression of retroviral-like particles and reverse transcriptase activity (
Table 1
| Disease | Retrotransposon | Mutation/Gene Referenced | Elevated Cytokines | CNS vs. Systemic |
|---|---|---|---|---|
| Multiple Sclerosis (MS) | HERV-W | IFNγ, IL-6, TNF-α | CNS | |
| Aicardi-Goutieres Syndrome (AGS) | LINE-1 | TREX1, RNaseH2 | TNF-α, IL-15, IFN-α | CNS |
| Rett Syndrome (RTT) | LINE-1 | MeCP2 | IL-6, IL-8 | CNS |
| Sporadic Amyotrophic Lateral Sclerosis (ALS) | HERV-K | TDP-43 | TNF-α, IL-6, IL-8, IL-1β | CNS |
| System Lupus Erythematosus (SLE) | HERV-E | Sgp3 | IL-15, IL-10, IFN α/β, IL-6 | Systemic |
| Aging-related pathologies | LINE-1 | SIRT6 | IFN | Systemic |
| Autism Spectrum Disorder (ASD) | LINE-1 | IFNγ, IL-1β, IL-6 | CNS |
Disease and associated retroelements.
Diseases listed with associated endogenous retroelement contributions and observed cytokine expression in vivo or in vitro. Genes listed were ones referenced in the main text. Last column addresses whether effects are primarily systemic or localized to CNS.
This work provided the initial evidence for retroviral-triggered HERV activation as a contributor to the pathology in neurological disorders (
LINE-1 Retrotransposons
LINE-1 elements are ubiquitous, autonomous retrotransposons with an estimated 500,000 copies contained within the human genome (
Full length, RC LINE-1 are 6 kb in length and contain a 5′ untranslated region (5′ UTR), two open reading frames (ORF1, 2), and a 3′ UTR punctuated with a poly-A tract (
Figure 2

LINE-1 retrotransposition cycle and host factor regulation. Structure of full-length genomic LINE-1. 5′ UTR contains sense and antisense promoter activity. Relative positions of ORF0, ORF1, and ORF2, 3′ UTR and a poly A tail are shown. EN denotes endonuclease, RT denotes reverse transcriptase, and C denotes cysteine-rich domain. RNA polymerase II mediates transcription of retrotransposition-competent LINE-1 sequence. This transcript is exported from the nucleus where it forms an RNP complex with ORF1p and ORF2p. Through a mechanism not well-understood, the RNP is imported into the nucleus to begin reverse transcription and integration through TPRT. The ORF2 EN nicks the bottom strand of the DNA, exposing a 3′ OH, which serves as a primer for the RT to generate the cDNA from the LINE-1 mRNA. How the second strand is synthesized and integrated is a poorly understood mechanism. LINE-1 is regulated at distinct intermediates of retrotransposition, indicated in red boxes.
The LINE-1 transcription start site begins at the RNA polymerase II promoter region, or more precisely, within the first 100 base pairs of the 5′ UTR (
Heterogeneity of Insertional Preferences and Distribution of Retrotransposons Across Different Populations
Selective processes and insertion bias impact the distribution of LINE-1 elements in the genome (
A recent meta-analysis of engineered LINE-1 insertions by Flasch and colleagues reported a strong bias for LINE-1 insertional preferences. Wild-type LINE-1 EN preferentially nicks the lagging strand of DNA replication fork, resulting in cDNA insertions into leading strand templates (
There is heterogeneity in the distribution of endogenous retroelements across different human populations: from the presence/absence of the element to single nucleotide polymorphisms (SNPs) [Figure 3; (
Figure 3

Somatic vs. Germline Insertions. Differences between the heritability of germline vs. somatic retrotransposon insertions. (A) Somatic insertions lead to mosaicism within the individual but are not inherited. (B) Generally, germline or early embryonic insertions are incorporated into the three germ layers and are present in all tissue types. (C) Example of polymorphisms across different populations based on the presence or absence of an insertion.
As a consequence, polymorphisms can generate variability in activity levels of retrotransposons. Indeed, allelic variability within the LINE-1 elements was demonstrated to have up to 16-fold differences in activity (
Polymorphisms are observed with HERV elements as well. Next generation sequencing (NGS) characterized unfixed HERV-K insertions across different human populations (
In summary, a myriad of selective processes influences the distribution and insertional preferences of retrotransposons. This allows for genomic mosaicism within a single individual as well as polymorphisms across different human populations.
Cellular Impact of LINE-1 Retrotransposition
There are innumerable ways in which retrotransposons can influence the genome and impact cellular function (Figure 4). LINE-1 elements generate structural variation/instability within the genome and subsequently interfere with host gene expression. In this section, we review the insertional and transcriptional impact of LINE-1 elements in the human genome.
Figure 4

Consequences of LINE-1 retrotransposition. Ongoing retrotransposition generates genomic instability and consequently interferes with host gene expression at many levels. Consequences include disruption of gene function due to LINE-1 insertions, as well as generation of mis-spliced or prematurely truncated transcripts. Insertions have been shown to impact host gene expression through changes in epigenetic patterning and LINE-1 promoter activity. This figure is adapted from Macia et al. (
The current rate of LINE-1 retrotransposition has been estimated to occur between 1 out of 20 and 1 out of 200 births, depending upon the method used in the analysis (
Insertional mutagenesis is not the only hazard for our cells, the presence of both sense and antisense promoter within the 5′UTR of LINE-1 elements can activate upstream or downstream transcription [(
Not only does the activity from the LINE-1 promoter at insertion sites contribute to aberrant host gene expression; LINE-1 insertions can also create splicing variants, generate mis-spliced or prematurely truncated transcripts, promote transcriptional termination or even promote changes to our epigenome (Figure 4). Splicing of pre-mRNAs is a tightly regulated process as it contributes to proteomic diversity and modulates gene expression. RNA extracted from human Ntera2 and Sk-Br-3 cancer cells, which express high levels of LINE-1 transcripts, identified many functional splice sites within the 5′UTR (
LINE-1 elements not only create changes in splicing; LINE-1 loci that contain premature stop codons may still encode for truncated ORF2 proteins with a retained functional EN domain (
Finally, LINE-1 can also alter the epigenome; methylation of LINE and SINE CpG islands leads to “epigenetic patterning” and subsequent silencing of neighboring gene promoters [(
Cellular Responses to Retrotransposition
Intrinsic immune responses to viral pathogens are co-opted to restrict retroviruses and retrotransposons as well. Given that these retroelements can impact the cell in a myriad of ways, the host genome has coevolved to employ a variety of responses to repress aberrant activity.
LINE-1 Transcriptional Repression
Transcriptional repression is a major mechanism of TE regulation and can be achieved with the deposition of repressive epigenetic modifications. DNA methylation, in the form of 5-methylcytosine (5 mC) and N6-methyladenine (6 mA) are widely used chemical modifications in eukaryotes and higher organisms [Figure 2; (
Transcriptional silencing of retrotransposons can be induced by DNA methylation or histone modifications, but TEs also harbor binding sites for many transcription factors, enabling context-specific transcriptional regulation. The Kruppel-associated box (KRAB)-containing zinc finger proteins (KZFPs) are key regulators of TE activity—often repressing TEs expressed in early embryos (73, 74). Mechanistically, repression is mediated once the C-terminus tandem array of zinc finger motifs binds to target TE sequences and the KRAB domain recruits and tethers to the cofactor KAP-1 (KRAB associated protein 1). KAP-1 then functions as a scaffold for chromatin modifying complexes such as SETDB1 (Set Domain Bifurcated-1) and H3K9 methyl transferase [Figure 2; (75, 76)].
In order for KAP1 to target a specific retroelement, the associating KRAB-ZFP must evolve to bind to that specific regulatory sequence. This is usually followed by mutations in this sequence, such that retrotransposons evade repression; a true evolutionary arms race (77). A recent study by Trono et al. elucidated the role of KZFPs on TEs during embryonic genome activation (EGA), demonstrating that a large proportion of TE-embedded regulatory sequences have been co-opted to serve as lineage- or tissue-specific enhancers of gene expression (78). Authors observed clustered TE sequences of the evolutionarily recent SVA, LTR5Hs-HERVK, and LTR7-HERVH in human embryonic stem cells (hESC) during EGA. These sequences were shown to strongly associate with members of the Kruppel-like factor (KLF) family of transcription factors, notably KLF4. Clustered regularly spaced short palindrome repeats—interference (CRISPRi) targeting of these TE sequences led to up- and downregulation of genes near the target vicinity. For example, CRISPRi of an LTR5Hs-based enhancer resulted in a significant downregulation of PRODH, a neuron-specific gene located 2 kb downstream from the enhancer. Thus, TEs which possess embedded enhancer sequences could subsequently exert large transcriptional influence in hESCs during EGA. By examining the degree of conservation within the zinc fingerprints, evolutionarily recent human KZFPs were shown to target TE subfamilies of similar ages (78). In sum, these recent studies demonstrate the intricate, coevolutionary dynamic between KZFPs and TEs.
However, there is some evidence indicating that this arms-race hypothesis may be too simplistic (79, 80). Imbeault et al. performed a clustering and aging analysis of various KZFPs to estimate their evolutionary ages. These conserved sequences were aligned against various transposable element subfamilies; many transposable element-KZFP pairs were found to be highly conserved long after the transposable elements lost their ability to mobilize (80). In some cases, KZFPs appear much earlier than their TE target, illustrating a complex co-option model where specific regulatory networks are established (78, 80). This is an example whereby the host facilitates the impact TEs can have by regulating their disruptive capacity. In addition, host cells even use conserved TE sequences to their advantage by setting up tissue-specific transcriptional networks.
Post-transcriptional Regulation of LINE-1 Elements
LINE-1 can be regulated post-transcriptionally by small RNAs, like microRNAs (miRNAs) or PIWI-interacting RNAs (piRNAs). Small RNAs can act via targeted RNA degradation, reviewed in Heras et al. (81) and Mita and Boeke (82). The role of RNA interference (RNAi) effectors in regulating TE transcripts is substantial; RNA-induced silencing complex (RISC) pathways are common cellular processes that utilize endonucleolytic cleavage to degrade TE transcripts (83, 84). Mutations to the Dicer protein, a component of the RISC complex, result in elevated transcription of LINE-1 elements (
Post-translational Mediated Repression
The LINE-1 RNP complex, a retrotransposition intermediate, is commonly targeted for destabilization and degradation (93). The zinc-finger protein ZAP, in addition to targeting several viral families, has been suggested to colocalize with LINE-1 RNA in cytoplasmic stress granules to promote loss of RNP integrity and inhibit LINE and Alu retrotransposition [Figure 2; (94–96)]. Post-transcriptional modifications of LINE-1 mRNAs within the RNP complex offers another way of restricting mobility. TUT7 (terminal uridyl transferase 7) in cooperation with MOV10, transfers uridine residues to LINE-1 mRNA in the cytoplasm. MOV10, a helicase, displaces ORF1p to allow for cytoplasmic 3′ uridylation—ultimately inhibiting ORF2p RT initiation within the nucleus [Figure 2; (97)]. In addition, the APOBEC family of enzymes, specifically APOBEC3G and APOBEC3F, have been shown to work through a process independent of cytosine deamination to selectively inhibit Alu retrotransposition, possibly by destabilizing the RNP complex [Figure 2; (98)]. APOBEC3B/F also strongly interfere with LINE-1 activity; catalytically inactive APOBEC mutants maintained LINE-1 inhibition, also indicating a deamination-independent mechanism (99, 100), while APOBEC3A has been proposed to localize in the nucleus to deaminate the transiently expressed LINE-1 ssDNA that appears during integration and prevent retrotransposition (101). Even with the plethora of host mechanisms put in place to repress endogenous retroelements, de novo insertions still take place within somatic tissues, with substantial LINE-1 retrotransposition occurring in neural lineages.
LINE-1 in the Developing Brain
A plethora of evidence supports that both endogenous and engineered LINE-1 retrotransposition can occur pre and post-mitotically in the healthy and diseased brain, reviewed in Suarez et al. (102). New retrotransposition events can alter gene expression and ultimately influence cellular phenotype; in the healthy brain this is thought to contribute to neuronal somatic diversification (
Retrotransposition during neural development may contribute to “genome plasticity” and neuronal diversity by allowing for variation in genomic DNA from cell to cell. By studying the effects of retroelements during neurogenesis, one can examine the early fate choices between different cell lineages (103). Muotri et al. reports a 10-fold increase in LINE-1 promoter during the first 24 h of neuronal induction, consistent with downregulation of the Sox2 promoter (103). It was proposed that subtle changes to LINE-1 promoter methylation may explain the selective activity levels in NPCs; perhaps that the LINE-1 promoter is temporarily released from epigenetic suppression during neurogenesis (
Mobile Elements and Neurodegenerative Disorders
There has been an increasing interest in studying endogenous retroelements as their activation has been observed and implicated in a variety of neurological disorders (Table 1). For example, all three HERV-K structural genes (gag, pol, env) have been shown to have increased expression in patients with sporadic ALS when compared to healthy controls (110). ALS is neurodegenerative disease characterized by loss of both upper and lower motor neurons. A number of studies have established the presence of retroviral RT activity in the serum of ALS patients (111, 112). Higher expression of HERV K-Env—a powerful immunopathogenic envelope protein—is observed in cortical pyramidal and spinal neurons in post-mortem brain tissue of ALS patients (110). It is not currently known what triggers expression of HERV-K in adult neurons; however, activation of HERV-K genes was shown to decrease dendritic length, branching, and complexity of transgenic mice motor neurons (110).
Abnormalities in transactive response DNA-binding protein 43 (TDP-43) is likewise observed in the majority of sporadic ALS cases (Table 1). TDP-43 is a dimeric nuclear protein and part of the heterogenous nuclear ribonucleoprotein family (hnRNP) (113). In the CNS, its function is broadly categorized as a regulator of pre and post-transcriptional events as it binds to UG-rich motifs in single-stranded RNA/DNA (113, 114). Crosslinking immunoprecipitation (CLIP-seq) and chromatin immunoprecipitation (ChIP) data exhibits TDP-43 binding broadly to retrotransposon-derived transcripts in human brain tissue and directly to the HERV-K LTR sequence, respectively (110, 115). A study conducted by Lisa Krug et al. addressed whether functionally abnormal TDP-43 expression in Drosophila causes a derepression of retrotransposable elements and if so, whether this contributes to a degenerative phenotype (116). Expression of human TDP-43 (hTDP-43) was shown to induce broad retrotransposon transcript expression in Drosophila neurons and glia. Glial expression of hTDP-43 causes a remarkable reduction of Dicer-2/Argonaute2 mediated silencing while causally inducing DNA-damage mediated cell death (116). In a more recent study, analysis of diseased neuronal nuclei from brain tissue of patients with frontotemporal degeneration ALS (FTD-ALS), provides insight for molecular changes associated with TDP-43 loss. Liu et al. utilized fluorescence-activated cell sorting (FACS) to fractionate diseased neurons followed by ATAC-seq to quantify chromatin accessibility (117). Loss of nuclear TDP-43 was associated with chromatin decondensation around LINE-1 elements. Although it is unclear whether decondensation of LINE-1 elements is a direct result of TDP-43 protein loss, there appeared to be some specificity or preference in decondensation of LINE-1 elements over other repetitive sequences (117). Together, these findings in humans and vertebrate models, suggest that unregulated retroelement expression is somewhat involved in the pathology of ALS, although there is no evidence that it is the primary cause of the syndrome. Potential therapy in the form of antiretroviral RTi is also underway in clinical trials of ALS patients (118, 119).
Sporadic Alzheimer's Disease (SAD) has also been linked to retroelement activation; however, studies have displayed conflicting results on whether LINE-1 sequences are upregulated in patients with SAD (120, 121). “Mosaic genomic recombination events” were observed within the Alzheimer's-related gene, amyloid precursor protein (APP), in neurons of patients with SAD (122). These variants, which lacked intronic sequences, were termed “genomic cDNAs” (gencDNAs). It was hypothesized that they originated from RNA and required endogenous RT activity to insert into double strand breaks. Addition of nucleoside reverse transcriptase inhibitors (nRTi) abacavir (ABC) and azidothymidine (AZT) prevented the production of gencDNAs, further encouraging their therapeutic potential (122). In order to determine the effect of Alzheimer's Tau pathology on TE activity, wild-type and Tau mutant Drosophila were profiled for TE activation including 8 LTR retrotransposons and 4 non-LTR retrotransposons (123). Authors observed a significant increase in expression in three of the 12 TEs assessed in the mutant fly brains (copia, gypsy and het-a) suggesting a possible Tau- associated mechanism for TE activation (123).
Retroelement recombination events are also implicated in early onset Parkinson's Disease (PD). Whole genome sequencing analysis of three families with early onset PD revealed five different structural variations in the PRKN (parkin RBR E3 ubiquitin protein ligase) gene. Structural variation formation is proposed to occur with non-allelic homologous recombination. LTR and non-LTR retrotransposon sequences were identified within two kilobases of the deletion break point, suggesting that the deletions may have originated due to retrotransposition events (124). The link between retroelement activation in neurodegenerative disorders is present but not fully established. We consistently see an upregulation of retroelements in the diseased state, but we do not fully understand how this is initiated or whether it directly contributes to disease pathology. The following section will review the evidence which supports endogenous retroelements as initiators of inflammation and subsequent inflammatory responses in the diseased state.
TEs and Inflammation
The immune system protects against viral infections through coordinated innate and adaptive immune responses and while the contribution of innate immunity to anti-viral defenses has been extensively studied, little is known about the contribution of transposable elements to immune responses exempt of viral infection. When viral DNA is present in the cytoplasm, it triggers activation of the cGAS-STING pathway, subsequently producing interferons to initiate an inflammatory response (Figure 5). The interferon responses elicited during the targeting of virus-infected cells may be mechanistically linked to deregulating retroelement production (125). There is mounting evidence that endogenous retroelements play a large role in initiating neuroinflammation. Endogenous nucleic acid detection by the innate immune system underlies many autoimmune diseases (126) When there is an inflammatory response but no viral infection, what is the role of retroelements? More specifically, how are these engaging the pathophysiological pathways leading to features of the disease pathology?
Figure 5

Hypothesized model of retroelement-mediated neuroinflammation. Environmental or cellular triggers may activate retrotransposon transcription. Production of pathogenic HERV Envelope proteins (Env) or cytoplasmic accumulation of LINE-1 ssDNA activates an innate immune response. Astrocytes become activated, releasing proinflammatory cytokines and reactive oxidative species (ROS). This has toxic effects on neighboring neurons and could promote morphological and synaptogenic defects, subsequently promoting neuropathophysiological effects. Figure is adapted from Thomas et al. (
There is increasing interest in studying endogenous retroelements as contributors to a variety of inflammatory and neurodegenerative disorders. Diseases such as MS and Aicardi-Goutières syndrome (AGS) have retrotransposon intermediates linked as key effectors of inflammation (
Aging
Mechanisms repressing LINE-1 activity are shown to be less efficient during the aging process. A recent study by De Cecco and colleagues demonstrates increased LINE-1 transcript levels in senescent cells. The accumulation of the cytoplasmic LINE-1 cDNA drives expression of the senescence- associated secretory phenotype (SASP). A type-I interferon (IFN) response is typical with age-associated inflammation in several tissues (Table 1). Liver and adipose tissue of 26-month-old mice showed significant increase in LINE-1 mRNA expression when compared to mice at 5 months. IFN-I and SASP response genes were assessed by RT-qPCR and showed the same trend. This response is antagonized through the use of reverse-transcriptase inhibitors (RTi). Mice treated with RTis demonstrate a reduced IFN response and associated inflammation (128). However, RTis have exhibited an intrinsic anti-inflammatory property, leading some to believe the effects as non-specific (129). The effects of LINE-1 activity in aging were also examined in the mono-ADP-ribosylase/deacetylase protein SIRT6 (Silent Mating Type Information Regulation 2 Homolog 6) deficient mice. SIRT6 KO mice display a severe aging phenotype, with a lifespan of 35 days (130). SIRT6 KO mice demonstrate high levels of LINE-1 expression due to SIRT6's repressive role in ribosylating KAP1 (131, 132). Without SIRT6, LINE-1 cytoplasmic DNA levels increased, triggering cGAS (cyclic GMP-AMP synthase) -mediated IFN response. Treatment with the RTi inhibitors lamivudine and stavudine, significantly expanded the lifespan of the mice while also improving body mass, mobility and behavior phenotypes (130). These results further implicate LINE-1 as a contributor to the pathology of age-related diseases. Although further investigation is needed regarding the mechanisms in which new L1 copies are generated in the cytoplasm, these novel data encourage the potential therapeutic use of RTis for various age-associated conditions.
Multiple Sclerosis
Following the original identification of retroviral-like particles (
Systemic Lupus Erythematosus
Elevated HERV transcription has been implicated in systemic lupus erythematosus (SLE) pathogenesis. HERV-E mRNA expression levels were found to be higher in lupus CD4+ T cells than in cells from healthy controls (141) but the full contribution of HERV activity to SLE etiology is not known. Deletions in the genes encoding for the KZFP, SNERV1/2 (suppressor of non-ecotropic ERV-1/2) resulted in a 2-fold increase in gene expression of six genes directly overlapping a non-ecotropic ERV sequence (NEERV) (127). The NEERV envelope glycoprotein gp70 is a major immunoantigen and promotes nephritis in murine models (142). SNERV1/2 bind to the gp70-associated loci, Sgp3, and recruit KAP1 to repress transcription. SNERV deletions in New Zealand Black mice resulted in elevated NEERV transcripts and gp70 expression. These results indicate that defects in HERV repression may promote human lupus pathogenesis (127).
Autism Spectrum Disorders
Activity of LINE-1 elements have additionally been implicated in many Autism Spectrum Disorders (ASD) phenotypes. Researchers have found a reduction of methylation and an increase in LINE-1 expression in ASD post-mortem brains (143, 144). ASD is a developmental disorder that impairs communication and behavior; however, little is known about the etiology of the disease. At the cellular level, researchers have found that individuals with ASD frequently show widespread inflammation and elevated brain cytokine expression. Additionally, a growing body of evidence supports the view that a chronic inflammation may contribute to autism symptomatology, with active neuroinflammatory processes being found throughout the brain in both cerebral cortex and cerebellum of patients with autism (145–148). Although new LINE-1 insertions seem to occur frequently in neurons, little is known about the contribution of this element in glial cells. It is becoming increasingly evident that under pathological conditions, there is a non-cell autonomous effect in the CNS, in which glial cells are as vulnerable as neurons (149). Astrocytes are often indicated as the contributors to disease phenotypes and in some instances, the disease initiators (150–152). Accumulating evidence links the cytokine dysregulation and persistent inflammatory phenotypes seen in mice and iPSC-derived models with astrocyte functional abnormalities [Figure 5; (153, 154)]. Indeed, ASD-derived astrocytes secrete elevated cytokines such as interleukin-6 (IL-6), which may interfere with proper neuronal development (155).
Rett Syndrome
Rett Syndrome (RTT), once considered part of ASD, is an X-linked progressive neurodevelopmental disorder with autistic features, characterized predominantly by various mutations in the methyl CpG binding protein-2 (MeCP2) (156). Post-mortem brain tissue samples analyzed showed higher genomic LINE-1 ORF2 sequences in RTT patients when compared to controls (157). Muotri et al. demonstrated that MeCP2 loss of function increases susceptibility for LINE-1 insertions because the 5′UTR sequence within the LINE-1 promoter are targets of MeCP2-mediated transcriptional repression [Figure 2; (157)]. Conditioned media taken from RTT mutant astrocytes had adverse effects on wild type mouse neurons. After just 24 h, neurons grown in RTT astrocyte conditioned media had significantly smaller soma sizes, shorter neurites and less terminal ends (158). Re-expression of MeCP2 specifically in astrocytes improved locomotion, anxiety levels, and prolonged the lifespan of globally deficient MeCP2 mice. Even more, restoration of MeCP2 in astrocytes restored VGlut1 levels and dendritic morphology of neurons in vivo (159). More research must be conducted to confirm whether the abnormally high presence of LINE-1 retroelements seen in RTT contributes to: (1) the inflammatory response seen in astrocytes and (2) disease progression.
Aicardi-Goutières Syndrome
Indeed, it has been found that the accumulation of LINE-1 copies in neurodevelopmental diseases promote inflammatory effects in astrocytes, as is in the case of AGS (
Conclusion
Reviewed here are recent reports which highlight aberrant TE activation as contributors to a variety of neurological, neurodegenerative, and autoimmune pathologies. Activation of retroelements confer genomic and cellular instability as TEs can disrupt coding regions, rewire transcriptional networks, and modify epigenetic and post-transcriptional regulation of gene expression. Indeed, retrotransposons have evaded evolutionary attempts at repression and contribute to somatic mosaicism. In the diseased state, where repression or regulation of retrotransposons is diminished, expression of endogenous nucleic acids are upregulated, promoting a response from the host, similar to the one that occurs upon a viral infection or to environmental triggers. In most cases, the cell will initiate an interferon response. Persistent inflammation leads to functional abnormalities and disease phenotypes; therefore, we speculate that retroelement misregulation impacts human pathogenesis to a larger extent than previously thought.
Statements
Author contributions
AS wrote the manuscript with help from AM and ARM.
Funding
This work was supported by grants from the National Institutes of Health through the NIH R01MH094753. The work was also supported by the California Institute for Regenerative Medicine (CIRM) award DISC1-08825. AM was supported by a NARSAD Young Investigator grant number 25400.
Conflict of interest
ARM is a co-founder and has equity interest in TISMOO, a company dedicated to genetic analysis and brain organoid modeling focusing on therapeutic applications customized for autism spectrum disorder and other neurological disorders with genetic origins. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict of interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
McClintockB. Controlling elements and the gene. Cold Spring Harb Symp Quant Biol. (1956) 21:197–216. 10.1101/SQB.1956.021.01.017
2.
LevinHLMoranJV. Dynamic interactions between transposable elements and their hosts. Nat Rev Genet. (2011) 12:615–27. 10.1038/nrg3030
3.
GoodierJLKazazianHHJr. Retrotransposons revisited: the restraint and rehabilitation of parasites. Cell. (2008) 135:23–35. 10.1016/j.cell.2008.09.022
4.
LanderESLintonLMBirrenBNusbaumCZodyMCBaldwinJet al. International Human Genome Sequencing. Initial sequencing and analysis of the human genome. Nature. (2001) 409:860–921. 10.1038/35057062
5.
MaciaABlanco-JimenezEGarcia-PerezJL. Retrotransposons in pluripotent cells: impact and new roles in cellular plasticity. Biochim Biophys Acta. (2015) 1849:417–26. 10.1016/j.bbagrm.2014.07.007
6.
Garcia-PerezJLWidmannTJAdamsIR. The impact of transposable elements on mammalian development. Development. (2016) 143:4101–14. 10.1242/dev.132639
7.
Munoz-LopezMGarcia-PerezJL. DNA transposons: nature and applications in genomics. Curr Genomics. (2010) 11:115–28. 10.2174/138920210790886871
8.
RichardsonSRMorellSFaulknerGJ. L1 retrotransposons and somatic mosaicism in the brain. Annu Rev Genet. (2014) 48:1–27. 10.1146/annurev-genet-120213-092412
9.
SmitAF. Identification of a new, abundant superfamily of mammalian LTR-transposons. Nucleic Acids Res. (1993) 21:1863–72. 10.1093/nar/21.8.1863
10.
CordauxRBatzerMA. The impact of retrotransposons on human genome evolution. Nat Rev Genet. (2009) 10:691–703. 10.1038/nrg2640
11.
DewannieuxMEsnaultCHeidmannT. LINE-mediated retrotransposition of marked Alu sequences. Nat Genet. (2003) 35:41–8. 10.1038/ng1223
12.
NelsonPNCarnegiePRMartinJDavari EjtehadiHHooleyPRodenDet al. Demystified. Human endogenous retroviruses. Mol Pathol. (2003) 56:11–8. 10.1136/mp.56.1.11
13.
MagerDLStoyeJP. Mammalian endogenous retroviruses. Microbiol Spectr. (2015) 3:MDNA3-0009-2014. 10.1128/microbiolspec.MDNA3-0009-2014
14.
WildschutteJHWilliamsZHMontesionMSubramanianRPKiddJMCoffinJM. Discovery of unfixed endogenous retrovirus insertions in diverse human populations. Proc Natl Acad Sci USA. (2016) 113:E2326–34. 10.1073/pnas.1602336113
15.
GrandiNTramontanoE. HERV envelope proteins: physiological role and pathogenic potential in cancer and autoimmunity. Front Microbiol. (2018) 9:462. 10.3389/fmicb.2018.00462
16.
PerronHSuhMLalandeBGratacapBLaurentAStoebnerPet al. Herpes simplex virus ICP0 and ICP4 immediate early proteins strongly enhance expression of a retrovirus harboured by a leptomeningeal cell line from a patient with multiple sclerosis. J Gen Virol. (1993) 74 (Pt 1):65–72. 10.1099/0022-1317-74-1-65
17.
PerronHGarsonJABedinFBesemeFParanhos-BaccalaGKomurian-PradelFet al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The collaborative research group on Multiple Sclerosis. Proc Natl Acad Sci USA. (1997) 94:7583–8. 10.1073/pnas.94.14.7583
18.
BlondJLBesemeFDuretLBoutonOBedinFPerronHet al. Molecular characterization and placental expression of HERV-W, a new human endogenous retrovirus family. J Virol. (1999) 73:1175–85.
19.
KuryPNathACreangeADoleiAMarchePGoldJet al. Human endogenous retroviruses in neurological diseases. Trends Mol Med. (2018) 24:379–94. 10.1016/j.molmed.2018.02.007
20.
BoissinotSEntezamAFuranoAV. Selection against deleterious LINE-1-containing loci in the human lineage. Mol Biol Evol. (2001) 18:926–35. 10.1093/oxfordjournals.molbev.a003893
21.
BoissinotSFuranoAV. Adaptive evolution in LINE-1 retrotransposons. Mol Biol Evol. (2001) 18:2186–94. 10.1093/oxfordjournals.molbev.a003765
22.
OstertagEMKazazianHHJr. Twin priming: a proposed mechanism for the creation of inversions in L1 retrotransposition. Genome Res. (2001) 11:2059–2065. 10.1101/gr.205701
23.
PavlicekAPacesJZikaRHejnarJ. Length distribution of long interspersed nucleotide elements (LINEs) and processed pseudogenes of human endogenous retroviruses: implications for retrotransposition and pseudogene detection. Gene. (2002) 300:189–94. 10.1016/S0378-1119(02)01047-8
24.
BrouhaBSchustakJBadgeRMLutz-PriggeSFarleyAHMoranJVet al. Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA. (2003) 100:5280–5. 10.1073/pnas.0831042100
25.
SwergoldGD. Identification, characterization, and cell specificity of a human LINE-1 promoter. Mol Cell Biol. (1990) 10:6718–29. 10.1128/MCB.10.12.6718
26.
SpeekM. Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol. (2001) 21:1973–85. 10.1128/MCB.21.6.1973-1985.2001
27.
DenliAMNarvaizaIKermanBEPenaMBennerCMarchettoMCet al. Primate-specific ORF0 contributes to retrotransposon-mediated diversity. Cell. (2015) 163:583–93. 10.1016/j.cell.2015.09.025
28.
MartinSLBushmanFD. Nucleic acid chaperone activity of the ORF1 protein from the mouse LINE-1 retrotransposon. Mol Cell Biol. (2001) 21:467–75. 10.1128/MCB.21.2.467-475.2001
29.
MartinSLCruceanuMBranciforteDPWai-LunLiKwokSCHodgesRSet al. LINE-1 retrotransposition requires the nucleic acid chaperone activity of the ORF1 protein. J Mol Biol. (2005) 348:549–61. 10.1016/j.jmb.2005.03.003
30.
MathiasSLScottAFKazazianHHJrBoekeJDGabrielA. Reverse transcriptase encoded by a human transposable element. Science. (1991) 254:1808–1810. 10.1126/science.1722352
31.
FengQMoranJVKazazianHHJrBoekeJD. Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell. (1996) 87:905–16. 10.1016/S0092-8674(00)81997-2
32.
LavieLMaldenerEBrouhaBMeeseEUMayerJ. The human L1 promoter: variable transcription initiation sites and a major impact of upstream flanking sequence on promoter activity. Genome Res. (2004) 14:2253–60. 10.1101/gr.2745804
33.
DoucetAJHulmeAESahinovicEKulpaDAMoldovanJBKoperaHCet al. Characterization of LINE-1 ribonucleoprotein particles. PLoS Genet. (2010) 6:e1001150. 10.1371/journal.pgen.1001150
34.
ElbarbaryRALucasBAMaquatLE. Retrotransposons as regulators of gene expression. Science. (2016) 351:aac7247. 10.1126/science.aac7247
35.
JurkaJ. Sequence patterns indicate an enzymatic involvement in integration of mammalian retroposons. Proc Natl Acad Sci USA. (1997) 94:1872–7. 10.1073/pnas.94.5.1872
36.
CostGJBoekeJD. Targeting of human retrotransposon integration is directed by the specificity of the L1 endonuclease for regions of unusual DNA structure. Biochemistry. (1998) 37:18081–93. 10.1021/bi981858s
37.
MonotCKuciakMViolletSMirAAGabusCDarlixJLet al. The specificity and flexibility of l1 reverse transcription priming at imperfect T-tracts. PLoS Genet. (2013) 9:e1003499. 10.1371/journal.pgen.1003499
38.
ThomasCATejwaniLTrujilloCANegraesPDHeraiRHMesciPet al. Modeling of TREX1-dependent autoimmune disease using human stem cells highlights L1 accumulation as a source of neuroinflammation. Cell Stem Cell. (2017) 21:319–31 e318. 10.1016/j.stem.2017.07.009
39.
Benitez-GuijarroMLopez-RuizCTarnauskaiteZMurinaOMian MohammadMWilliamsTCet al. RNase H2, mutated in Aicardi-Goutieres syndrome, promotes LINE-1 retrotransposition. EMBO J. (2018) 37:e98506. 10.15252/embj.201798506
40.
CheungVGSpielmanRSEwensKGWeberTMMorleyMBurdickJT. Mapping determinants of human gene expression by regional and genome-wide association. Nature. (2005) 437:1365–9. 10.1038/nature04244
41.
GrahamTBoissinotS. The genomic distribution of L1 elements: the role of insertion bias and natural selection. J Biomed Biotechnol. (2006) 2006:75327. 10.1155/JBB/2006/75327
42.
FlaschDAMaciaASanchezLLjungmanMHerasSRGarcia-PerezJLet al. Genome-wide de novo L1 retrotransposition connects endonuclease activity with replication. Cell. (2019) 177:837–51.e28. 10.1016/j.cell.2019.02.050
43.
SultanaTvan EssenDSiolOBailly-BechetMPhilippeCZineEl Aabidine Aet al. The landscape of L1 retrotransposons in the human genome is shaped by pre-insertion sequence biases and post-insertion selection. Mol Cell. (2019) 74:555–70.e7. 10.1016/j.molcel.2019.02.036
44.
LutzSMVincentBJKazazianHHJrBatzerMAMoranJV. Allelic heterogeneity in LINE-1 retrotransposition activity. Am J Hum Genet. (2003) 73:1431–7. 10.1086/379744
45.
KonkelMKWangJLiangPBatzerMA. Identification and characterization of novel polymorphic LINE-1 insertions through comparison of two human genome sequence assemblies. Gene. (2007) 390:28–38. 10.1016/j.gene.2006.07.040
46.
PhilippeCVargas-LandinDBDoucetAJvan EssenDVera-OtarolaJKuciakMet al. Activation of individual L1 retrotransposon instances is restricted to cell-type dependent permissive loci. Elife. (2016) 5:e13926. 10.7554/eLife.13926
47.
CoufalNGGarcia-PerezJLPengGEYeoGWMuYLovciMTet al. L1 retrotransposition in human neural progenitor cells. Nature. (2009) 460:1127–31. 10.1038/nature08248
48.
BelancioVPRoy-EngelAMPochampallyRRDeiningerP. Somatic expression of LINE-1 elements in human tissues. Nucleic Acids Res. (2010) 38:3909–22. 10.1093/nar/gkq132
49.
BaillieJKBarnettMWUptonKRGerhardtDJRichmondTADe SapioFet al. Somatic retrotransposition alters the genetic landscape of the human brain. Nature. (2011) 479:534–7. 10.1038/nature10531
50.
MarchiEKanapinAMagiorkinisGBelshawR. Unfixed endogenous retroviral insertions in the human population. J Virol. (2014) 88:9529–37. 10.1128/JVI.00919-14
51.
ChenJMStensonPDCooperDNFerecC. A systematic analysis of LINE-1 endonuclease-dependent retrotranspositional events causing human genetic disease. Hum Genet. (2005) 117:411–27. 10.1007/s00439-005-1321-0
52.
GilbertNLutz-PriggeSMoranJV. Genomic deletions created upon LINE-1 retrotransposition. Cell. (2002) 110:315–25. 10.1016/S0092-8674(02)00828-0
53.
SlotkinRKMartienssenR. Transposable elements and the epigenetic regulation of the genome. Nat Rev Genet. (2007) 8:272–85. 10.1038/nrg2072
54.
NigumannPRedikKMatlikKSpeekM. Many human genes are transcribed from the antisense promoter of L1 retrotransposon. Genomics. (2002) 79:628–34. 10.1006/geno.2002.6758
55.
MaciaAMunoz-LopezMCortesJLHastingsRKMorellSLucena-AguilarGet al. Epigenetic control of retrotransposon expression in human embryonic stem cells. Mol Cell Biol. (2011) 31:300–16. 10.1128/MCB.00561-10
56.
MatlikKRedikKSpeekM. L1 antisense promoter drives tissue-specific transcription of human genes. J Biomed Biotechnol. (2006) 2006:71753. 10.1155/JBB/2006/71753
57.
WeberBKimhiSHowardGEdenALykoF. Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene. (2010) 29:5775–84. 10.1038/onc.2010.227
58.
BelancioVPHedgesDJDeiningerP. LINE-1 RNA splicing and influences on mammalian gene expression. Nucleic Acids Res. (2006) 34:1512–21. 10.1093/nar/gkl027
59.
SorekR. The birth of new exons: mechanisms and evolutionary consequences. RNA. (2007) 13:1603–8. 10.1261/rna.682507
60.
ShenSLinLCaiJJJiangPKenkelEJStroikMRet al. Widespread establishment and regulatory impact of Alu exons in human genes. Proc Natl Acad Sci USA. (2011) 108:2837–42. 10.1073/pnas.1012834108
61.
Perepelitsa-BelancioVDeiningerP. RNA truncation by premature polyadenylation attenuates human mobile element activity. Nat Genet. (2003) 35:363–6. 10.1038/ng1269
62.
KinesKJSokolowskiMdeHaroDLChristianCMBelancioVP. Potential for genomic instability associated with retrotranspositionally-incompetent L1 loci. Nucleic Acids Res. (2014) 42:10488–502. 10.1093/nar/gku687
63.
GasiorSLWakemanTPXuBDeiningerPL. The human LINE-1 retrotransposon creates DNA double-strand breaks. J Mol Biol. (2006) 357:1383–93. 10.1016/j.jmb.2006.01.089
64.
EstecioMRGallegosJDekmezianMLuYLiangSIssaJP. SINE retrotransposons cause epigenetic reprogramming of adjacent gene promoters. Mol Cancer Res. (2012) 10:1332–42. 10.1158/1541-7786.MCR-12-0351
65.
BaylinSBHermanJGGraffJRVertinoPMIssaJP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. (1998) 72:141–96. 10.1016/S0065-230X(08)60702-2
66.
WolffEMByunHMHanHFSharmaSNicholsPWSiegmundKDet al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet. (2010) 6:e1000917. 10.1371/journal.pgen.1000917
67.
DenizOFrostJMBrancoMR. Author correction: regulation of transposable elements by DNA modifications. Nat Rev Genet. (2019) 20:432. 10.1038/s41576-019-0117-3
68.
Garcia-PerezJLMarchettoMCMuotriARCoufalNGGageFHO'SheaKSet al. LINE-1 retrotransposition in human embryonic stem cells. Hum Mol Genet. (2007) 16:1569–77. 10.1093/hmg/ddm105
69.
Garcia-PerezJLMorellMScheysJOKulpaDAMorellSCarterCCet al. Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature. (2010) 466:769–73. 10.1038/nature09209
70.
KlawitterSFuchsNVUptonKRMunoz-LopezMShuklaRWangJet al. Author correction: reprogramming triggers endogenous L1 and Alu retrotransposition in human induced pluripotent stem cells. Nat Commun. (2018) 9:5398. 10.1038/s41467-018-07917-0
71.
HatanakaYInoueKOikawaMKamimuraSOgonukiNKodamaENet al. Histone chaperone CAF-1 mediates repressive histone modifications to protect preimplantation mouse embryos from endogenous retrotransposons. Proc Natl Acad Sci USA. (2015) 112:14641–6. 10.1073/pnas.1512775112
72.
ElsasserSJNohKMDiazNAllisCDBanaszynskiLA. Histone H3.3 is required for endogenous retroviral element silencing in embryonic stem cells. Nature. (2015) 522:240–4. 10.1038/nature14345
73.
ChuongEBEldeNCFeschotteC. Regulatory activities of transposable elements: from conflicts to benefits. Nat Rev Genet. (2017) 18:71–86. 10.1038/nrg.2016.139
74.
GuoGvon MeyennFRostovskayaMClarkeJDietmannSBakerDet al. Correction: epigenetic resetting of human pluripotency (10.1242/dev.146811). Development. (2018) 145:dev166397. 10.1242/dev.166397
75.
WolfGGreenbergDMacfarlanTS. Spotting the enemy within: targeted silencing of foreign DNA in mammalian genomes by the Kruppel-associated box zinc finger protein family. Mob DNA. (2015) 6:17. 10.1186/s13100-015-0050-8
76.
YangPWangYMacfarlanTS. The role of KRAB-ZFPs in transposable element repression and mammalian evolution. Trends Genet. (2017) 33:871–81. 10.1016/j.tig.2017.08.006
77.
JacobsFMGreenbergDNguyenNHaeusslerMEwingADKatzmanSet al. An evolutionary arms race between KRAB zinc-finger genes ZNF91/93 and SVA/L1 retrotransposons. Nature. (2014) 516:242–5. 10.1038/nature13760
78.
PontisJPlanetEOffnerSTurelliPDucJCoudrayAet al. Hominoid-specific transposable elements and KZFPs facilitate human embryonic genome activation and control transcription in naive human ESCs. Cell Stem Cell. (2019) 24:724–35.e5. 10.1016/j.stem.2019.03.012
79.
EccoGImbeaultMTronoD. KRAB zinc finger proteins. Development. (2017) 144:2719–29. 10.1242/dev.132605
80.
ImbeaultMHelleboidPYTronoD. KRAB zinc-finger proteins contribute to the evolution of gene regulatory networks. Nature. (2017) 543:550–4. 10.1038/nature21683
81.
HerasSRMaciasSCaceresJFGarcia-PerezJL. Control of mammalian retrotransposons by cellular RNA processing activities. Mob Genet Elements. (2014) 4:e28439. 10.4161/mge.28439
82.
MitaPBoekeJD. How retrotransposons shape genome regulation. Curr Opin Genet Dev. (2016) 37:90–100. 10.1016/j.gde.2016.01.001
83.
YangNKazazianHHJr. L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells. Nat Struct Mol Biol. (2006) 13:763–71. 10.1038/nsmb1141
84.
BodakMYuJCiaudoC. Regulation of LINE-1 elements by miR-128 is not conserved in mouse embryonic stem cells. Front Genet. (2018) 9:683. 10.3389/fgene.2018.00683
85.
IdicaASevrioukovEAZisoulisDGHamdorfMDaugaardIKadandalePet al. MicroRNA miR-128 represses LINE-1 (L1) retrotransposition by down-regulating the nuclear import factor TNPO1. J Biol Chem. (2017) 292:20494–508. 10.1074/jbc.M117.807677
86.
FungLGuzmanHSevrioukovEIdicaAParkEBochnakianAet al. miR-128 restriction of LINE-1 (L1) retrotransposition is dependent on targeting hnRNPA1 mRNA. Int J Mol Sci. (2019) 20:1955. 10.3390/ijms20081955
87.
Pinol-RomaSDreyfussG. Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature. (1992) 355:730–2. 10.1038/355730a0
88.
IzaurraldeEJarmolowskiABeiselCMattajIWDreyfussGFischerU. A role for the M9 transport signal of hnRNP A1 in mRNA nuclear export. J Cell Biol. (1997) 137:27–35. 10.1083/jcb.137.1.27
89.
SiomiHDreyfussG. A nuclear localization domain in the hnRNP A1 protein. J Cell Biol. (1995) 129:551–60. 10.1083/jcb.129.3.551
90.
GoodierJLCheungLEKazazianHHJr. Mapping the LINE1 ORF1 protein interactome reveals associated inhibitors of human retrotransposition. Nucleic Acids Res. (2013) 41:7401–19. 10.1093/nar/gkt512
91.
TothKFPezicDStuweEWebsterA. The piRNA pathway guards the germline genome against transposable elements. Adv Exp Med Biol. (2016) 886:51–77. 10.1007/978-94-017-7417-8_4
92.
NewkirkSJLeeSGrandiFCGaysinskayaVRosserJMVanden BergNet al. Intact piRNA pathway prevents L1 mobilization in male meiosis. Proc Natl Acad Sci USA. (2017) 114:E5635–E5644. 10.1073/pnas.1701069114
93.
KulpaDAMoranJV. Ribonucleoprotein particle formation is necessary but not sufficient for LINE-1 retrotransposition. Hum Mol Genet. (2005) 14:3237–48. 10.1093/hmg/ddi354
94.
GoodierJLZhangLVetterMRKazazianHHJr. LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including components of RNA interference RNA-induced silencing complex. Mol Cell Biol. (2007) 27:6469–6483. 10.1128/MCB.00332-07
95.
GoodierJLPereiraGCCheungLERoseRJKazazianHHJr. The broad-spectrum antiviral protein ZAP restricts human retrotransposition. PLoS Genet. (2015) 11:e1005252. 10.1371/journal.pgen.1005252
96.
MoldovanJBMoranJV. The zinc-finger antiviral protein ZAP inhibits LINE and alu retrotransposition. PLoS Genet. (2015) 11:e1005121. 10.1371/journal.pgen.1005121
97.
WarkockiZKrawczykPSAdamskaDBijataKGarcia-PerezJLDziembowskiA. Uridylation by TUT4/7 restricts retrotransposition of human LINE-1s. Cell. (2018) 174:1537–48 e1529. 10.1016/j.cell.2018.07.022
98.
HulmeAEBogerdHPCullenBRMoranJV. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene. (2007) 390:199–205. 10.1016/j.gene.2006.08.032
99.
MuckenfussHHamdorfMHeldUPerkovicMLowerJCichutekKet al. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J Biol Chem. (2006) 281:22161–72. 10.1074/jbc.M601716200
100.
StengleinMDHarrisRS. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J Biol Chem. (2006) 281:16837–41. 10.1074/jbc.M602367200
101.
RichardsonSRNarvaizaIPlaneggerRAWeitzmanMDMoranJV. APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition. Elife. (2014) 3:e02008. 10.7554/eLife.02008
102.
SuarezNAMaciaAMuotriAR. LINE-1 retrotransposons in healthy and diseased human brain. Dev Neurobiol. (2018) 78:434–55. 10.1002/dneu.22567
103.
MuotriARChuVTMarchettoMCDengWMoranJVGageFH. Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature. (2005) 435:903–10. 10.1038/nature03663
104.
EvronyGDCaiXLeeEHillsLBElhosaryPCLehmannHSet al. Single-neuron sequencing analysis of L1 retrotransposition and somatic mutation in the human brain. Cell. (2012) 151:483–96. 10.1016/j.cell.2012.09.035
105.
UptonKRGerhardtDJJesuadianJSRichardsonSRSanchez-LuqueFJBodeaGOet al. Ubiquitous L1 mosaicism in hippocampal neurons. Cell. (2015) 161:228–39. 10.1016/j.cell.2015.03.026
106.
ErwinJAPaquolaACMSingerTGallinaINovotnyMQuayleCet al. Author correction: L1-associated genomic regions are deleted in somatic cells of the healthy human brain. Nat Neurosci. (2018) 21:1016. 10.1038/s41593-018-0131-3
107.
SingerTMcConnellMJMarchettoMCCoufalNGGageFH. LINE-1 retrotransposons: mediators of somatic variation in neuronal genomes?Trends Neurosci. (2010) 33:345–54. 10.1016/j.tins.2010.04.001
108.
Salvador-PalomequeCSanchez-LuqueFJFortunaPRJEwingADWolvetangEJRichardsonSRet al. Dynamic methylation of an L1 transduction family during reprogramming and neurodifferentiation. Mol Cell Biol. (2019) 39(7). 10.1128/MCB.00499-18
109.
Sanchez-LuqueFJKempenMHCGerdesPVargas-LandinDBRichardsonSRTroskieR-Let al. LINE-1 evasion of epigenetic repression in humans. Mol Cell. (2019) 75:P590–604.E12. 10.1016/j.molcel.2019.05.024
110.
LiWLeeMHHendersonLTyagiRBachaniMSteinerJet al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. (2015) 7:307ra153. 10.1126/scitranslmed.aac8201
111.
AndrewsWDTukePWAl-ChalabiAGaudinPIjazSPartonMJet al. Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. J Med Virol. (2000) 61:527–532. 10.1002/1096-9071(200008)61:4<527::AID-JMV17>3.0.CO;2-A
112.
SteeleAJAl-ChalabiAFerranteKCudkowiczMEBrownRHJrGarsonJA. Detection of serum reverse transcriptase activity in patients with ALS and unaffected blood relatives. Neurology. (2005) 64:454–8. 10.1212/01.WNL.0000150899.76130.71
113.
HergesheimerRCChamiAAde AssisDRVourc'hPAndresCRCorciaPet al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight?Brain. (2019) 142:1176–94. 10.1093/brain/awz078
114.
KuoPHDoudevaLGWangYTShenCKYuanHS. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. (2009) 37:1799–808. 10.1093/nar/gkp013
115.
LiWJinYPrazakLHammellMDubnauJ. Transposable elements in TDP-43-mediated neurodegenerative disorders. PLoS ONE. (2012) 7:e44099. 10.1371/journal.pone.0044099
116.
KrugLChatterjeeNBorges-MonroyRHearnSLiaoWWMorrillKet al. Retrotransposon activation contributes to neurodegeneration in a Drosophila TDP-43 model of ALS. PLoS Genet. (2017) 13:e1006635. 10.1371/journal.pgen.1006635
117.
LiuEYRussJCaliCPPhanJMAmlie-WolfALeeEB. Loss of nuclear TDP-43 is associated with decondensation of LINE retrotransposons. Cell Rep. (2019) 27:1409–21 e1406. 10.1016/j.celrep.2019.04.003
118.
DouvilleRLiuJRothsteinJNathA. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. (2011) 69:141–51. 10.1002/ana.22149
119.
AlfahadTNathA. Retroviruses and amyotrophic lateral sclerosis. Antiviral Res. (2013) 99:180–7. 10.1016/j.antiviral.2013.05.006
120.
BollatiVGalimbertiDPergoliLDalla ValleEBarrettaFCortiniFet al. DNA methylation in repetitive elements and Alzheimer disease. Brain Behav Immun. (2011) 25:1078–83. 10.1016/j.bbi.2011.01.017
121.
ProtasovaMSGusevFEGrigorenkoAPKuznetsovaILRogaevEIAndreevaTV. Quantitative analysis of L1-retrotransposons in Alzheimer's disease and aging. Biochemistry. (2017) 82:962–71. 10.1134/S0006297917080120
122.
LeeMHSiddowayBKaeserGESegotaIRiveraRRomanowWJet al. Publisher correction: somatic APP gene recombination in Alzheimer's disease and normal neurons. Nature. (2019) 566:E6. 10.1038/s41586-019-0905-0
123.
GuoCJeongHHHsiehYCKleinHUBennettDADe JagerPLet al. Tau activates transposable elements in Alzheimer's disease. Cell Rep. (2018) 23:2874–80. 10.1016/j.celrep.2018.05.004
124.
BravoPDarvishHTafakhoriAAzconaLJJohariAHJamaliFet al. Molecular characterization of PRKN structural variations identified through whole-genome sequencing. Mol Genet Genomic Med. (2018) 6:1243–8. 10.1002/mgg3.482
125.
MaciaATejwaniLMesciPMuotriAGarcia-PerezJL. Activity of retrotransposons in stem cells and differentiated cells. In: CristofariG, editor. Human Retrotransposons in Health and Disease. Cham: Springer (2017). 10.1007/978-3-319-48344-3_6
126.
VolkmanHEStetsonDB. The enemy within: endogenous retroelements and autoimmune disease. Nat Immunol. (2014) 15:415–22. 10.1038/ni.2872
127.
TregerRSPopeSDKongYTokuyamaMTauraMIwasakiA. The lupus susceptibility locus Sgp3 encodes the suppressor of endogenous retrovirus expression SNERV. Immunity. (2019) 50:334–47 e339. 10.1016/j.immuni.2018.12.022
128.
De CeccoMItoTPetrashenAPEliasAESkvirNJCriscioneSWet al. L1 drives IFN in senescent cells and promotes age-associated inflammation. Nature. (2019) 566:73–8. 10.1038/s41586-018-0784-9
129.
FowlerBJGelfandBDKimYKerurNTaralloVHiranoYet al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. (2014) 346:1000–3. 10.1126/science.1261754
130.
SimonMVan MeterMAblaevaJKeZGonzalezRSTaguchiTet al. LINE1 derepression in aged wild-type and SIRT6-deficient mice drives inflammation. Cell Metab. (2019) 29:871–85 e875. 10.1016/j.cmet.2019.02.014
131.
MostoslavskyRChuaKFLombardDBPangWWFischerMRGellonLet al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell. (2006) 124:315–29. 10.1016/j.cell.2005.11.044
132.
Van MeterMKashyapMRezazadehSGenevaAJMorelloTDSeluanovAet al. SIRT6 represses LINE1 retrotransposons by ribosylating KAP1 but this repression fails with stress and age. Nat Commun. (2014) 5:5011. 10.1038/ncomms6011
133.
ChristensenTDissing SorensenPRiemannHHansenHJMunchMHaahrSet al. Molecular characterization of HERV-H variants associated with multiple sclerosis. Acta Neurol Scand. (2000) 101:229–38. 10.1034/j.1600-0404.2000.101004229.x
134.
RollandAJouvin-MarcheEViretCFaureMPerronHMarchePN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14/TLR4 and promotes Th1-like responses. J Immunol. (2006) 176:7636–44. 10.4049/jimmunol.176.12.7636
135.
PerronHBernardCBertrandJBLangABPopaISanhadjiKet al. Endogenous retroviral genes, herpesviruses and gender in multiple sclerosis. J Neurol Sci. (2009) 286:65–72. 10.1016/j.jns.2009.04.034
136.
GottlePForsterMGruchotJKremerDHartungHPPerronHet al. Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination. Glia. (2019) 67:160–70. 10.1002/glia.23535
137.
DendrouCAFuggerLFrieseMA. Immunopathology of multiple sclerosis. Nat Rev Immunol. (2015) 15:545–58. 10.1038/nri3871
138.
MorandiETanasescuRTarlintonREConstantinescuCSZhangWTenchCet al. The association between human endogenous retroviruses and multiple sclerosis: a systematic review and meta-analysis. PLoS ONE. (2017) 12:e0172415. 10.1371/journal.pone.0172415
139.
SaresellaMRollandAMarventanoICavarrettaRCaputoDMarchePet al. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis. Mult Scler. (2009) 15:443–7. 10.1177/1352458508100840
140.
GoldJMartaMCMeierUCChristensenTMillerDAltmannDet al. Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results. Mult Scler J. (2016) 22:188–9. 10.1016/j.msard.2018.06.002
141.
WuZMeiXZhaoDSunYSongJPanWet al. DNA methylation modulates HERV-E expression in CD4+ T cells from systemic lupus erythematosus patients. J Dermatol Sci. (2015) 77:110–6. 10.1016/j.jdermsci.2014.12.004
142.
BaudinoLYoshinobuKMoritoNKikuchiSFossati-JimackLMorleyBJet al. Dissection of genetic mechanisms governing the expression of serum retroviral gp70 implicated in murine lupus nephritis. J Immunol. (2008) 181:2846–54. 10.4049/jimmunol.181.4.2846
143.
ShpylevaSMelnykSPavlivOPogribnyIJill JamesS. Overexpression of LINE-1 Retrotransposons in Autism Brain. Mol Neurobiol. (2018) 55:1740–9. 10.1007/s12035-017-0421-x
144.
TangsuwansriCSaeliwTThongkornSChonchaiyaWSuphapeetipornKMutiranguraAet al. Investigation of epigenetic regulatory networks associated with autism spectrum disorder (ASD) by integrated global LINE-1 methylation and gene expression profiling analyses. PLoS One. (2018) 13:e0201071. 10.1371/journal.pone.0201071
145.
VargasDLNascimbeneCKrishnanCZimmermanAWPardoCA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. (2005) 57:67–81.
146.
ThackerMAClarkAKMarchandFMcMahonSB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. (2007) 105:838–47.
147.
MorganJTChanaGPardoCAAchimCSemendeferiKBuckwalterJet al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. (2010) 68:368–76.
148.
KernJKGeierDASykesLKGeierMR. Relevance of neuroinflammation and encephalitis in autism. Front Cell Neurosci. (2015) 9:519. 10.3389/fncel.2015.00519
149.
OkabeYTakahashiTMitsumasuCKosaiKTanakaEMatsuishiT. Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome. PLoS ONE. (2012) 7:e35354. 10.1371/journal.pone.0035354
150.
Di GiorgioFPCarrascoMASiaoMCManiatisTEgganK. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci. (2007) 10:608–14.
151.
LobsigerCSClevelandDW. Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci. (2007) 10:1355–60.
152.
IlievaHPolymenidouMClevelandDW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol. (2009) 187:761–72. 10.1083/jcb.200908164
153.
CortelazzoADe FeliceCGuerrantiRSignoriniCLeonciniSPecorelliAet al. Subclinical inflammatory status in Rett syndrome. Mediators Inflamm. (2014) 2014:480980. 10.1155/2014/480980
154.
CortelazzoADe FeliceCDe FilippisBRicceriLLaviolaGLeonciniSet al. Persistent unresolved inflammation in the Mecp2-308 female mutated mouse model of rett syndrome. Mediators Inflamm. (2017) 2017:9467819. 10.1155/2017/9467819
155.
RussoFBFreitasBCPignatariGCFernandesIRSebatJMuotriARBet al. (2018). Modeling the interplay between neurons and astrocytes in autism using human induced pluripotent stem cells. Biol Psychiatry.83:569–78. 10.1016/j.biopsych.2017.09.021
156.
ZhaoBWuQYeAYGuoJZhengXYangXet al. Somatic LINE-1 retrotransposition in cortical neurons and non-brain tissues of Rett patients and healthy individuals. PLoS Genet. (2019) 15:e1008043. 10.1371/journal.pgen.1008043
157.
MuotriARMarchettoMCCoufalNGOefnerRYeoGNakashimaKet al. L1 retrotransposition in neurons is modulated by MeCP2. Nature. (2010) 468:443–6. 10.1038/nature09544
158.
WilliamsECZhongXMohamedALiRLiuYDongQet al. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet. (2014) 23:2968–80. 10.1093/hmg/ddu008
159.
LioyDTGargSKMonaghanCERaberJFoustKDKasparBKet al. A role for glia in the progression of Rett's syndrome. Nature. (2011) 475:497–500. 10.1038/nature10214
160.
CrowYJRehwinkelJ. Aicardi-Goutieres syndrome and related phenotypes: linking nucleic acid metabolism with autoimmunity. Hum Mol Genet. (2009) 18:R130–6. 10.1093/hmg/ddp293
161.
RiceGIMeyzerCBouazzaNHullyMBoddaertNSemeraroMet al. Reverse-transcriptase inhibitors in the aicardi-goutieres syndrome. N Engl J Med. (2018) 379:2275–7. 10.1056/NEJMc1810983
Summary
Keywords
LINE-1, HERV, retrotransposition, CNS, inflammation, reverse transcriptase inhibitors
Citation
Saleh A, Macia A and Muotri AR (2019) Transposable Elements, Inflammation, and Neurological Disease. Front. Neurol. 10:894. doi: 10.3389/fneur.2019.00894
Received
27 April 2019
Accepted
02 August 2019
Published
20 August 2019
Volume
10 - 2019
Edited by
Avindra Nath, National Institute of Neurological Disorders and Stroke, United States
Reviewed by
Hervé Perron, Independent Researcher, Geneva, Switzerland; Santiago Morell, University of Cambridge, United Kingdom; Carmen Salvador-Palomeque, The University of Queensland, Australia
Updates

Check for updates
Copyright
© 2019 Saleh, Macia and Muotri.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Alysson R. Muotri muotri@ucsd.edu
This article was submitted to Neuroinfectious Diseases, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.